Fig. 2. Effects of tirzepatide on systemic inflammation, cardiac injury and natriuretic peptide levels.

a, Least-squares mean changes from baseline in CRP plotted as a function of duration of treatment in participants randomized to tirzepatide (red circles) or placebo (black squares). b, The estimated mean treatment difference in the change in troponin T and NT-proBNP with tirzepatide (TZP) to baseline compared with placebo plotted as a function of duration of treatment. The error bars represent the s.e.m. for all panels; P values are two-sided for each time point comparison for a and b based upon comparing the least-squares means calculated from a mixed-model repeated-measures model incorporating baseline value, history of HF decompensation within 12 months, diabetes status, baseline BMI group (<35, ≥35 kg m⁻²), treatment assignment, time, and treatment × time interaction. No correction was made for multiple hypothesis testing.